The role of acetylation and deacetylation in cancer metabolism

Abstract

	•Protein acetylation and deacetylation are key regulators of metabolic reprogramming in tumour cells.
	•These modifications influence signalling pathways critical for tumour metabolism.
	•They modulate the activity of transcription factors that drive gene expression changes.
	•Metabolic enzymes are also affected, altering cellular metabolism to support tumour growth.

Keywords

acetylation / cancer / deacetylation / metabolic reprogramming

References

[1] Pavlova NN, Zhu J, Thompson CB. The hallmarks of cancer metabolism: still emerging. Cell Metab. 2022;34(3):355-377.

[2] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.

[3] Icard P, Shulman S, Farhat D, Steyaert JM, Alifano M, Lincet H. How the Warburg effect supports aggressiveness and drug resistance of cancer cells?. Drug Resist Updat. 2018;38:1-11.

[4] Finley LWS. What is cancer metabolism?. Cell. 2023;186(8):1670-1688.

[5] Xiao Y, Yu TJ, Xu Y, et al. Emerging therapies in cancer metabolism. Cell Metab. 2023;35(8):1283-1303.

[6] Li W, Li F, Zhang X, Lin HK, Xu C. Insights into the post-translational modification and its emerging role in shaping the tumor microenvironment. Signal Transduct Target Ther. 2021;6(1):422.

[7] Shvedunova M, Akhtar A. Modulation of cellular processes by histone and non-histone protein acetylation. Nat Rev Mol Cell Biol. 2022;23(5):329-349.

[8] Zhao S, Xu W, Jiang W, et al. Regulation of cellular metabolism by protein lysine acetylation. Science. 2010;327(5968):1000-1004.

[9] Chen L, Liu S, Tao Y. Regulating tumor suppressor genes: post-translational modifications. Signal Transduct Target Ther. 2020;5(1):90.

[10] Zhao Y, Yu T, Zhang N, et al. Nuclear E-cadherin acetylation promotes colorectal tumorigenesis via enhancing β-catenin activity. Mol Cancer Res. 2019;17(2):655-665.

[11] Ren G, Zhang G, Dong Z, et al. Recruitment of HDAC4 by transcription factor YY1 represses HOXB13 to affect cell growth in AR-negative prostate cancers. Int J Biochem Cell Biol. 2009;41(5):1094-1101.

[12] Gibbs A, Schwartzman J, Deng V, Alumkal J. Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proc Natl Acad Sci USA. 2009;106(39):16663-16668.

[13] Xiong SD, Yu K, Liu XH, et al. Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells. Int J Cancer. 2009;125(4):774-782.

[14] Ellmeier W, Seiser C. Histone deacetylase function in CD4(+) T cells. Nat Rev Immunol. 2018;18(10):617-634.

[15] Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192-1204.

[16] Lin M, He J, Zhang X, et al. Targeting fibrinogen-like protein 1 enhances immunotherapy in hepatocellular carcinoma. J Clin Invest. 2023;133(9):e164528.

[17] Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274-293.

[18] Mossmann D, Park S, Hall MN. mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat Rev Cancer. 2018;18(12):744-757.

[19] Tian LY, Smit DJ, Jücker M. The role of PI3K/AKT/mTOR signaling in hepatocellular carcinoma metabolism. Int J Mol Sci. 2023;24(3):2652.

[20] Lawan A, Bennett AM. Mitogen-activated protein kinase regulation in hepatic metabolism. Trends Endocrinol Metab. 2017;28(12):868-878.

[21] Garama DJ, White CL, Balic JJ, Gough DJ. Mitochondrial STAT3: powering up a potent factor. Cytokine. 2016;87:20-25.

[22] DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2(5):e1600200.

[23] Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science. 1987;235(4795):1492-1495.

[24] Shim H, Dolde C, Lewis BC, et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA. 1997;94(13):6658-6663.

[25] Sies H, Jones DP. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat Rev Mol Cell Biol. 2020;21(7):363-383.

[26] Averill-Bates D. Reactive oxygen species and cell signaling. Biochim Biophys Acta Mol Cell Res. 2024;1871(2):119573.

[27] Farria A, Li W, Dent SY. KATs in cancer: functions and therapies. Oncogene. 2015;34(38):4901-4913.

[28] Wang Z, Zang C, Cui K, et al. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell. 2009;138(5):1019-1031.

[29] Narita T, Weinert BT, Choudhary C. Functions and mechanisms of non-histone protein acetylation. Nat Rev Mol Cell Biol. 2019;20(3):156-174.

[30] Harachi M, Masui K, Cavenee WK, Mischel PS, Shibata N. Protein acetylation at the interface of genetics, epigenetics and environment in cancer. Metabolites. 2021;11(4):216.

[31] Chang HC, Guarente L. SIRT1 and other sirtuins in metabolism. Trends Endocrinol Metab. 2014;25(3):138-145.

[32] Ramaiah MJ, Tangutur AD, Manyam RR. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy. Life Sci. 2021;277:119504.

[33] Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: at the bench and bedside. Semin Cancer Biol. 2019;59:125-132.

[34] Glaviano A, Foo ASC, Lam HY, et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138.

[35] Chen XS, Li LY, Guan YD, Yang JM, Cheng Y. Anticancer strategies based on the metabolic profile of tumor cells: therapeutic targeting of the Warburg effect. Acta Pharmacol Sin. 2016;37(8):1013-1019.

[36] Lv D, Jia F, Hou Y, et al. Histone acetyltransferase KAT6A upregulates PI3K/AKT signaling through TRIM24 binding. Cancer Res. 2017;77(22):6190-6201.

[37] Chi Y, Xue J, Huang S, et al. CapG promotes resistance to paclitaxel in breast cancer through transactivation of PIK3R1/P50. Theranostics. 2019;9(23):6840-6855.

[38] Worby CA, Dixon JE. PTEN. Annu Rev Biochem. 2014;83:641-669.

[39] Okumura K, Mendoza M, Bachoo RM, DePinho RA, Cavenee WK, Furnari FB. PCAF modulates PTEN activity. J Biol Chem. 2006;281(36):26562-26568.

[40] Ikenoue T, Inoki K, Zhao B, Guan KL. PTEN acetylation modulates its interaction with PDZ domain. Cancer Res. 2008;68(17):6908-6912.

[41] Li Y, Tsang CK, Wang S, et al. MAF1 suppresses AKT-mTOR signaling and liver cancer through activation of PTEN transcription. Hepatology. 2016;63(6):1928-1942.

[42] Pan L, Lu J, Wang X, et al. Histone deacetylase inhibitor trichostatin a potentiates doxorubicin-induced apoptosis by up-regulating PTEN expression. Cancer. 2007;109(8):1676-1688.

[43] Xu C, Sun W, Liu J, Pu H, Li Y. MiR-342-3p inhibits LCSC oncogenicity and cell stemness through HDAC7/PTEN axis. Inflamm Res. 2022;71(1):107-117.

[44] Qian YY, Liu ZS, Yan HJ, Yuan YF, Levenson AS, Li K. Pterostilbene inhibits MTA1/HDAC1 complex leading to PTEN acetylation in hepatocellular carcinoma. Biomed Pharmacother. 2018;101:852-859.

[45] Oliva-González C, Uresti-Rivera EE, Galicia-Cruz OG, Jasso-Robles FI, Gandolfi AJ. Escudero-Lourdes C. The tumor suppressor phosphatase and tensin homolog protein (PTEN) is negatively regulated by NF-κb p50 homodimers and involves histone 3 methylation/deacetylation in UROtsa cells chronically exposed to monomethylarsonous acid. Toxicol Lett. 2017;280:92-98.

[46] Meng Z, Jia LF, Gan YH. PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition. Oncogene. 2016;35(18):2333-2344.

[47] Sundaresan NR, Pillai VB, Wolfgeher D, et al. The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Sci Signal. 2011;4(182):ra46.

[48] Yang WL, Wang J, Chan CH, et al. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science. 2009;325(5944):1134-1138.

[49] Yan Y, An J, Yang Y, et al. Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN-or SPOP-mutated prostate cancer. EMBO Mol Med. 2018;10(4):e8478.

[50] Long J, Fang WY, Chang L, et al. Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response. Leukemia. 2017;31(12):2761-2770.

[51] An P, Chen F, Li Z, et al. HDAC8 promotes the dissemination of breast cancer cells via AKT/GSK-3β/Snail signals. Oncogene. 2020;39(26):4956-4969.

[52] Zhou HZ, Zeng HQ, Yuan D, et al. NQO1 potentiates apoptosis evasion and upregulates XIAP via inhibiting proteasome-mediated degradation SIRT6 in hepatocellular carcinoma. Cell Commun Signal. 2019;17(1):168.

[53] Cai K, Wang B, Dou H, Luan R, Bao X, Chu J. IL-17A promotes the proliferation of human nasopharyngeal carcinoma cells through p300-mediated Akt1 acetylation. Oncol Lett. 2017;13(6):4238-4244.

[54] Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168(6):960-976.

[55] Knudsen JR, Fritzen AM, James DE, Jensen TE, Kleinert M, Richter EA. Growth factor-dependent and -independent activation of mTORC2. Trends Endocrinol Metab. 2020;31(1):13-24.

[56] Masui K, Tanaka K, Ikegami S, et al. Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance. Proc Natl Acad Sci USA. 2015;112(30):9406-9411.

[57] Ito A, Lai CH, Zhao X, et al. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. Embo j. 2001;20(6):1331-1340.

[58] Kobet E, Zeng X, Zhu Y, Keller D, Lu H. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc Natl Acad Sci USA. 2000;97(23):12547-12552.

[59] Duffy MJ, Synnott NC, O’Grady S Crown J. Targeting p53 for the treatment of cancer. Semin Cancer Biol. 2022;79:58-67.

[60] Cai M, Xu S, Jin Y, et al. hMOF induces cisplatin resistance of ovarian cancer by regulating the stability and expression of MDM2. Cell Death Discov. 2023;9(1):179.

[61] Patel N, Wang J, Shiozawa K, et al. HDAC2 regulates site-specific acetylation of MDM2 and its ubiquitination signaling in tumor suppression. iScience. 2019;13:43-54.

[62] Nihira NT, Ogura K, Shimizu K, et al. Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function. Sci Signal. 2017;10(466):eaai8026.

[63] Wang X, Taplick J, Geva N, Oren M. Inhibition of p53 degradation by Mdm2 acetylation. FEBS Lett. 2004;561(1-3):195-201.

[64] Ard PG, Chatterjee C, Kunjibettu S, Adside LR, Gralinski LE, McMahon SB. Transcriptional regulation of the mdm2 oncogene by p53 requires TRRAP acetyltransferase complexes. Mol Cell Biol. 2002;22(16):5650-5661.

[65] Herzig S, Shaw RJ. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol. 2018;19(2):121-135.

[66] Liang J, Mills GB. AMPK: a contextual oncogene or tumor suppressor?. Cancer Res. 2013;73(10):2929-2935.

[67] Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009;9(8):563-575.

[68] Bi L, Ren Y, Feng M, et al. HDAC11 regulates glycolysis through the LKB1/AMPK signaling pathway to maintain hepatocellular carcinoma stemness. Cancer Res. 2021;81(8):2015-2028.

[69] Jung TY, Ryu JE, Jang MM, et al. Naa20, the catalytic subunit of NatB complex, contributes to hepatocellular carcinoma by regulating the LKB1-AMPK-mTOR axis. Exp Mol Med. 2020;52(11):1831-1844.

[70] Pecoraro C, Faggion B, Balboni B, et al. GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer. Drug Resist Updat. 2021;58:100779.

[71] Mulholland DJ, Dedhar S, Wu H, Nelson CC. PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. Oncogene. 2006;25(3):329-337.

[72] Kim JW, Yang JH, Kim EJ. SIRT1 and AROS suppress doxorubicin-induced apoptosis via inhibition of GSK3β activity in neuroblastoma cells. Anim Cells Syst (Seoul). 2020;24(1):53-59.

[73] Jiang C, Liu J, Guo M, et al. The NAD-dependent deacetylase SIRT2 regulates T cell differentiation involved in tumor immune response. Int J Biol Sci. 2020;16(15):3075-3084.

[74] Kong J, Wang L, Ren L, et al. Triptolide induces mitochondria-mediated apoptosis of Burkitt’s lymphoma cell via deacetylation of GSK-3β by increased SIRT3 expression. Toxicol Appl Pharmacol. 2018;342:1-13.

[75] Song CL, Tang H, Ran LK, et al. Sirtuin 3 inhibits hepatocellular carcinoma growth through the glycogen synthase kinase-3β/BCL2-associated X protein-dependent apoptotic pathway. Oncogene. 2016;35(5):631-641.

[76] Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26(22):3279-3290.

[77] Drosten M, Barbacid M. Targeting the MAPK pathway in KRAS-driven tumors. Cancer Cell. 2020;37(4):543-550.

[78] Trejo-Solís C, Castillo-Rodríguez RA, Serrano-García N, et al. Metabolic roles of HIF1, c-Myc, and p53 in glioma cells. Metabolites. 2024;14(5):249.

[79] Dixon ZA, Nicholson L, Zeppetzauer M, et al. CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response. Haematologica. 2017;102(4):736-745.

[80] Yang MH, Nickerson S, Kim ET, et al. Regulation of RAS oncogenicity by acetylation. Proc Natl Acad Sci USA. 2012;109(27):10843-10848.

[81] Cheng D, Zhao L, Xu Y, et al. K-Ras promotes the non-small lung cancer cells survival by cooperating with sirtuin 1 and p27 under ROS stimulation. Tumour Biol. 2015;36(9):7221-7232.

[82] Shin DH, Jo JY, Choi M, Kim KH, Bae YK, Kim SS. Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer. Exp Mol Med. 2023;55(10):2220-2237.

[83] Yang MH, Laurent G, Bause AS, et al. HDAC6 and SIRT2 regulate the acetylation state and oncogenic activity of mutant K-RAS. Mol Cancer Res. 2013;11(9):1072-1077.

[84] Song HY, Biancucci M, Kang HJ, et al. SIRT2 deletion enhances KRAS-induced tumorigenesis in vivo by regulating K147 acetylation status. Oncotarget. 2016;7(49):80336-80349.

[85] Ullah R, Yin Q, Snell AH, Wan L. RAF-MEK-ERK pathway in cancer evolution and treatment. Semin Cancer Biol. 2022;85:123-154.

[86] Wu JY, Xiang S, Zhang M, et al. Histone deacetylase 6 (HDAC6) deacetylates extracellular signal-regulated kinase 1 (ERK1) and thereby stimulates ERK1 activity. J Biol Chem. 2018;293(6):1976-1993.

[87] Cea M, Cagnetta A, Adamia S, et al. Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. Blood. 2016;127(9):1138-1150.

[88] Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234-248.

[89] Vaupel P, Multhoff G. Revisiting the Warburg effect: historical dogma versus current understanding. J Physiol. 2021;599(6):1745-1757.

[90] Li YJ, Zhang C, Martincuks A, Herrmann A, Yu H. STAT proteins in cancer: orchestration of metabolism. Nat Rev Cancer. 2023;23(3):115-134.

[91] Zheng X, Xu M, Yao B, Wang C, Jia Y, Liu Q. IL-6/STAT3 axis initiated CAFs via up-regulating TIMP-1 which was attenuated by acetylation of STAT3 induced by PCAF in HCC microenvironment. Cell Signal. 2016;28(9):1314-1324.

[92] Yuan ZL, Guan YJ, Chatterjee D, Chin YE. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science. 2005;307(5707):269-273.

[93] He Z, Wang J, Zhu C, et al. Exosome-derived FGD5-AS1 promotes tumor-associated macrophage M2 polarization-mediated pancreatic cancer cell proliferation and metastasis. Cancer Lett. 2022;548:215751.

[94] Xiang X, Kuang W, Yu C, et al. Tex10 interacts with STAT3 to regulate hepatocellular carcinoma growth and metastasis. Mol Carcinog. 2023;62(12):1974-1989.

[95] Xiang Y, Li JP, Guo W, et al. Novel interactions between ERα-36 and STAT3 mediate breast cancer cell migration. Cell Commun Signal. 2019;17(1):93.

[96] Lee JL, Wang MJ, Chen JY. Acetylation and activation of STAT3 mediated by nuclear translocation of CD44. J Cell Biol. 2009;185(6):949-957.

[97] Li XR, Cheng X, Sun J, et al. Acetylation-dependent glutamate receptor GluR signalosome formation for STAT3 activation in both transcriptional and metabolism regulation. Cell Death Discov. 2021;7(1):11.

[98] Wang L, Shi H, Zhang X, et al. I157172, a novel inhibitor of cystathionine γ-lyase, inhibits growth and migration of breast cancer cells via SIRT1-mediated deacetylation of STAT3. Oncol Rep. 2019;41(1):427-436.

[99] Chen Y, Zhu Y, Sheng Y, et al. SIRT1 downregulated FGB expression to inhibit RCC tumorigenesis by destabilizing STAT3. Exp Cell Res. 2019;382(2):111466.

[100] Wang W, Hu Y, Yang C, et al. Decreased NAD activates STAT3 and integrin pathways to drive epithelial-mesenchymal transition. Mol Cell Proteomics. 2018;17(10):2005-2017.

[101] Wang W, Li F, Xu Y, et al. JAK1-mediated Sirt1 phosphorylation functions as a negative feedback of the JAK1-STAT3 pathway. J Biol Chem. 2018;293(28):11067-11075.

[102] Ma L, Huang C, Wang XJ, et al. Lysyl oxidase 3 is a dual-specificity enzyme involved in STAT3 deacetylation and deacetylimINATION MODUlation. Mol Cell. 2017;65(2):296-309.

[103] Lei Y, Liu L, Zhang S, et al. Hdac7 promotes lung tumorigenesis by inhibiting Stat3 activation. Mol Cancer. 2017;16(1):170.

[104] Xu YS, Liang JJ, Wang Y, et al. STAT3 undergoes acetylation-dependent mitochondrial translocation to regulate pyruvate metabolism. Sci Rep. 2016;6:39517.

[105] Cheng Y, Holloway MP, Nguyen K, et al. XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer. Mol Cancer Ther. 2014;13(3):675-686.

[106] Liu Y, Duan X, Zhang C, et al. KAT6B may be applied as a potential therapeutic target for glioma. J Oncol. 2022;2022:2500092.

[107] Minami J, Suzuki R, Mazitschek R, et al. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia. 2014;28(3):680-689.

[108] Zhang W, Patil S, Chauhan B, et al. FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression. J Biol Chem. 2006;281(15):10105-10117.

[109] Saline M, Badertscher L, Wolter M, et al. AMPK and AKT protein kinases hierarchically phosphorylate the N-terminus of the FOXO1 transcription factor, modulating interactions with 14-3-3 proteins. J Biol Chem. 2019;294(35):13106-13116.

[110] Guo Y, Ye Q, Deng P, et al. Spermine synthase and MYC cooperate to maintain colorectal cancer cell survival by repressing Bim expression. Nat Commun. 2020;11(1):3243.

[111] Dong ZB, Wu HM, He YC, et al. MiRNA-124-3p.1 sensitizes hepatocellular carcinoma cells to sorafenib by regulating FOXO3a by targeting AKT2 and SIRT1. Cell Death Dis. 2022;13(1):35.

[112] Adlakha YK, Saini N. miR-128 exerts pro-apoptotic effect in a p53 transcription-dependent and -independent manner via PUMA-Bak axis. Cell Death Dis. 2013;4(3):e542.

[113] Jang EH, Lee JH, Kim SA. Acute valproate exposure induces mitochondrial biogenesis and autophagy with FOXO3a modulation in SH-SY5Y cells. Cells. 2021;10(10).

[114] Huo L, Bai X, Wang Y, Wang M. Betulinic acid derivative B10 inhibits glioma cell proliferation through suppression of SIRT1, acetylation of FOXO3a and upregulation of Bim/PUMA. Biomed Pharmacother. 2017;92:347-355.

[115] Song S, Tang H, Quan W, Shang A, Ling C. Estradiol initiates the immune escape of non-small cell lung cancer cells via ERβ/SIRT1/FOXO3a/PD-L1 axis. Int Immunopharmacol. 2022;107:108629.

[116] Wang F, Chan CH, Chen K, Guan X, Lin HK, Tong Q. Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3 ubiquitination and degradation. Oncogene. 2012;31(12):1546-1557.

[117] Aimjongjun S, Mahmud Z, Jiramongkol Y, et al. Lapatinib sensitivity in nasopharyngeal carcinoma is modulated by SIRT2-mediated FOXO3 deacetylation. BMC Cancer. 2019;19(1):1106.

[118] Liu J, Duan Z, Guo W, et al. Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer. Nat Commun. 2018;9(1):5200.

[119] Han LL, Jia L, Wu F, Huang C. Sirtuin6 (SIRT6) promotes the EMT of hepatocellular carcinoma by stimulating autophagic degradation of E-cadherin. Mol Cancer Res. 2019;17(11):2267-2280.

[120] Consolaro F, Ghaem-Maghami S, Bortolozzi R, et al. FOXO3a and posttranslational modifications mediate glucocorticoid sensitivity in B-ALL. Mol Cancer Res. 2015;13(12):1578-1590.

[121] Pramanik KC, Fofaria NM, Gupta P, Srivastava SK. CBP-mediated FOXO-1 acetylation inhibits pancreatic tumor growth by targeting SirT. Mol Cancer Ther. 2014;13(3):687-698.

[122] Yang Y, Hou H, Haller EM, Nicosia SV, Bai W. Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. Embo j. 2005;24(5):1021-1032.

[123] Zhang P, Tu B, Wang H, et al. Tumor suppressor p53 cooperates with SIRT6 to regulate gluconeogenesis by promoting FoxO1 nuclear exclusion. Proc Natl Acad Sci USA. 2014;111(29):10684-10689.

[124] Zhao Y, Yang J, Liao W, et al. Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity. Nat Cell Biol. 2010;12(7):665-675.

[125] Li Y, Zheng J, Huo Q, Chen Z, Chen J, Xu X. Chidamide suppresses the growth of cholangiocarcinoma by inhibiting HDAC3 and promoting FOXO1 acetylation. Stem Cells Int. 2022;2022:3632549.

[126] Zhang L, Cai M, Gong Z, et al. Geminin facilitates FoxO3 deacetylation to promote breast cancer cell metastasis. J Clin Invest. 2017;127(6):2159-2175.

[127] Sewastianik T, Szydlowski M, Jablonska E, et al. FOXO1 is a TXN-and p300-dependent sensor and effector of oxidative stress in diffuse large B-cell lymphomas characterized by increased oxidative metabolism. Oncogene. 2016;35(46):5989-6000.

[128] Masui K, Tanaka K, Akhavan D, et al. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab. 2013;18(5):726-739.

[129] Jie M, Wu Y, Gao M, et al. CircMRPS35 suppresses gastric cancer progression via recruiting KAT7 to govern histone modification. Mol Cancer. 2020;19(1):56.

[130] Kastenhuber ER, Lowe SW. Putting p53 in context. Cell. 2017;170(6):1062-1078.

[131] Kruse JP, Gu W. Modes of p53 regulation. Cell. 2009;137(4):609-622.

[132] Liu J, Zhang C, Hu W, Feng Z. Tumor suppressor p53 and its mutants in cancer metabolism. Cancer Lett. 2015;356:197-203. 2 Pt A.

[133] Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell. 1997;90(4):595-606.

[134] Ye C, Cheng Y, Qian X, Zhong B, Ma J, Guo H. The CDK4/6 inhibitor palbociclib induces cell senescence of high-grade serous ovarian cancer through acetylation of p53. Biochem Genet. 2024;62(6):5115-5128.

[135] Magni M, Buscemi G, Maita L, et al. TSPYL2 is a novel regulator of SIRT1 and p300 activity in response to DNA damage. Cell Death Differ. 2019;26(5):918-931.

[136] Kim MK, Song JY, Koh DI, et al. Reciprocal negative regulation between the tumor suppressor protein p53 and B cell CLL/lymphoma 6 (BCL6) via control of caspase-1 expression. J Biol Chem. 2019;294(1):299-313.

[137] Oh M, Lee JH, Moon H, Hyun YJ, Lim HS. A chemical inhibitor of the Skp2/p300 interaction that promotes p53-mediated apoptosis. Angew Chem Int Ed Engl. 2016;55(2):602-606.

[138] Wang J, Qian J, Hu Y, et al. ArhGAP30 promotes p53 acetylation and function in colorectal cancer. Nat Commun. 2014;5:4735.

[139] Kim MK, Jeon BN, Koh DI, et al. Regulation of the cyclin-dependent kinase inhibitor 1A gene (CDKN1A) by the repressor BOZF1 through inhibition of p53 acetylation and transcription factor Sp1 binding. J Biol Chem. 2013;288(10):7053-7064.

[140] Li Y, Li X, Fan G, et al. Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing family tumors. Cancer Lett. 2012;320(1):14-22.

[141] Wang X, Xie Q, Ji Y, et al. Targeting KRAS-mutant stomach/colorectal tumors by disrupting the ERK2-p53 complex. Cell Rep. 2023;42(1):111972.

[142] Xu X, Zhang C, Xu H, Wu L, Hu M, Song L. Autophagic feedback-mediated degradation of IKKα requires CHK1-and p300/CBP-dependent acetylation of p53. J Cell Sci. 2020;133(22):jcs246868.

[143] Kim WJ, Rivera MN, Coffman EJ, Haber DA. The WTX tumor suppressor enhances p53 acetylation by CBP/p300. Mol Cell. 2012;45(5):587-597.

[144] Wu ZZ, Sun NK, Chao CC. Knockdown of CITED2 using short-hairpin RNA sensitizes cancer cells to cisplatin through stabilization of p53 and enhancement of p53-dependent apoptosis. J Cell Physiol. 2011;226(9):2415-2428.

[145] Wu Y, Sun Y, Xu B, Yang M, Wang X, Zhao X. SCARNA10 regulates p53 acetylation-dependent transcriptional activity. Biochem Biophys Res Commun. 2023;669:38-45.

[146] Dai C, Shi D, Gu W. Negative regulation of the acetyltransferase TIP60-p53 interplay by UHRF1 (ubiquitin-like with PHD and RING finger domains 1). J Biol Chem. 2013;288(27):19581-19592.

[147] Liu T, Wang X, Hu W, et al. Epigenetically down-regulated acetyltransferase PCAF increases the resistance of colorectal cancer to 5-fluorouracil. Neoplasia. 2019;21(6):557-570.

[148] Rokudai S, Laptenko O, Arnal SM, Taya Y, Kitabayashi I, Prives C. MOZ increases p53 acetylation and premature senescence through its complex formation with PML. Proc Natl Acad Sci USA. 2013;110(10):3895-3900.

[149] Liu X, Tan Y, Zhang C, et al. NAT10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2. EMBO Rep. 2016;17(3):349-366.

[150] Cai W, Su L, Liao L, et al. PBRM1 acts as a p53 lysine-acetylation reader to suppress renal tumor growth. Nat Commun. 2019;10(1):5800.

[151] Lin XL, Li K, Yang Z, Chen B, Zhang T. Dulcitol suppresses proliferation and migration of hepatocellular carcinoma via regulating SIRT1/p53 pathway. Phytomedicine. 2020;66:153112.

[152] Kang YJ, Kwon YH, Jang JY, et al. MHY2251, a new SIRT1 inhibitor, induces apoptosis via JNK/p53 pathway in HCT116 human colorectal cancer cells. Biomol Ther (Seoul). 2023;31(1):73-81.

[153] Xiong Y, Xu S, Fu B, et al. Vitamin C-induced competitive binding of HIF-1α and p53 to ubiquitin E3 ligase CBL contributes to anti-breast cancer progression through p53 deacetylation. Food Chem Toxicol. 2022;168:113321.

[154] Kim U, Kim KS, Park JK, Um HD. Hyperacetylation of the C-terminal domain of p53 inhibits the formation of the p53/p21 complex. Biochem Biophys Res Commun. 2022;635:52-56.

[155] Jia X, Liu H, Ren X, et al. Nucleolar protein NOC4L inhibits tumorigenesis and progression by attenuating SIRT1-mediated p53 deacetylation. Oncogene. 2022;41(39):4474-4484.

[156] Pant K, Mishra AK, Pradhan SM, et al. Butyrate inhibits HBV replication and HBV-induced hepatoma cell proliferation via modulating SIRT-1/Ac-p53 regulatory axis. Mol Carcinog. 2019;58(4):524-532.

[157] He X, Maimaiti M, Jiao Y, Meng X, Li H. Sinomenine induces G1-phase cell cycle arrest and apoptosis in malignant glioma cells via downregulation of sirtuin 1 and induction of p53 acetylation. Technol Cancer Res Treat. 2018;17:1533034618770305.

[158] De U, Son JY, Sachan R, et al. A new synthetic histone deacetylase inhibitor, MHY2256, induces apoptosis and autophagy cell death in endometrial cancer cells via p53 acetylation. Int J Mol Sci. 2018;19(9):2743.

[159] Shu Y, Ren L, Xie B, Liang Z, Chen J. MiR-204 enhances mitochondrial apoptosis in doxorubicin-treated prostate cancer cells by targeting SIRT1/p53 pathway. Oncotarget. 2017;8(57):97313-97322.

[160] Hoffmann G, Breitenbücher F, Schuler M, Ehrenhofer-Murray AE. A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer. J Biol Chem. 2014;289(8):5208-5216.

[161] Zhao J, Wozniak A, Adams A, et al. SIRT7 regulates hepatocellular carcinoma response to therapy by altering the p53-dependent cell death pathway. J Exp Clin Cancer Res. 2019;38(1):252.

[162] Kim JH, Kim D, Cho SJ, et al. Identification of a novel SIRT7 inhibitor as anticancer drug candidate. Biochem Biophys Res Commun. 2019;508(2):451-457.

[163] Wei Z, Ye Y, Liu C, et al. MIER2/PGC1A elicits sunitinib resistance via lipid metabolism in renal cell carcinoma. J Adv Res. 2024.

[164] Yu X, Li H, Zhu M, et al. Involvement of p53 acetylation in growth suppression of cutaneous T-cell lymphomas induced by HDAC inhibition. J Invest Dermatol. 2020;140(10):2009-2022. e2004.

[165] Zhang Y, Chen J, Wu SS, et al. HOXA10 knockdown inhibits proliferation, induces cell cycle arrest and apoptosis in hepatocellular carcinoma cells through HDAC1. Cancer Manag Res. 2019;11:7065-7076.

[166] Yun T, Yu K, Yang S, et al. Acetylation of p53 protein at lysine 120 up-regulates Apaf-1 protein and sensitizes the mitochondrial apoptotic pathway. J Biol Chem. 2016;291(14):7386-7395.

[167] Miyajima C, Inoue Y, Hayashi H. Pseudokinase tribbles 1 (TRB1) negatively regulates tumor-suppressor activity of p53 through p53 deacetylation. Biol Pharm Bull. 2015;38(4):618-624.

[168] Li H, Song C, Zhang Y, et al. Transgelin promotes glioblastoma stem cell hypoxic responses and maintenance through p53 acetylation. Adv Sci (Weinh). 2024;11(7):e2305620.

[169] Li Z, Hao Q, Luo J, et al. USP4 inhibits p53 and NF-κB through deubiquitinating and stabilizing HDAC2. Oncogene. 2016;35(22):2902-2912.

[170] Lee YH, Seo D, Choi KJ, et al. Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2. Cancer Res. 2014;74(17):4752-4761.

[171] Brandl A, Wagner T, Uhlig KM, et al. Dynamically regulated sumoylation of HDAC2 controls p53 deacetylation and restricts apoptosis following genotoxic stress. J Mol Cell Biol. 2012;4(5):284-293.

[172] Shan X, Fu YS, Aziz F, Wang XQ, Yan Q, Liu JW. Ginsenoside Rg3 inhibits melanoma cell proliferation through down-regulation of histone deacetylase 3 (HDAC3) and increase of p53 acetylation. PLoS One. 2014;9(12):e115401.

[173] Ryu HW, Shin DH, Lee DH, et al. HDAC6 deacetylates p53 at lysines 381/382 and differentially coordinates p53-induced apoptosis. Cancer Lett. 2017;391:162-171.

[174] Qi J, Singh S, Hua WK, et al. HDAC8 inhibition specifically targets Inv(16) acute myeloid leukemic stem cells by restoring p53 acetylation. Cell Stem Cell. 2015;17(5):597-610.

[175] Shimano H, Sato R. SREBP-regulated lipid metabolism: convergent physiology-divergent pathophysiology. Nat Rev Endocrinol. 2017;13(12):710-730.

[176] Krycer JR, Sharpe LJ, Luu W, Brown AJ. The Akt-SREBP nexus: cell signaling meets lipid metabolism. Trends Endocrinol Metab. 2010;21(5):268-276.

[177] Song NY, Na HK, Baek JH, Surh YJ. Docosahexaenoic acid inhibits insulin-induced activation of sterol regulatory-element binding protein 1 and cyclooxygenase-2 expression through upregulation of SIRT1 in human colon epithelial cells. Biochem Pharmacol. 2014;92(1):142-148.

[178] Ponugoti B, Kim DH, Xiao Z, et al. SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. J Biol Chem. 2010;285(44):33959-33970.

[179] Masoud GN, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015;5(5):378-389.

[180] Gabriely G, Wheeler MA, Takenaka MC, Quintana FJ. Role of AHR and HIF-1α in glioblastoma metabolism. Trends Endocrinol Metab. 2017;28(6):428-436.

[181] Düvel K, Yecies JL, Menon S, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell. 2010;39(2):171-183.

[182] Dodd KM, Yang J, Shen MH, Sampson JR, Tee AR. mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene. 2015;34(17):2239-2250.

[183] Lim JH, Lee YM, Chun YS, Chen J, Kim JE, Park JW. Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. Mol Cell. 2010;38(6):864-878.

[184] Tan P, Wang M, Zhong A, et al. SRT1720 inhibits the growth of bladder cancer in organoids and murine models through the SIRT1-HIF axis. Oncogene. 2021;40(42):6081-6092.

[185] Joo HY, Jung JK, Kim MY, et al. NADH elevation during chronic hypoxia leads to VHL-mediated HIF-1α degradation via SIRT1 inhibition. Cell Biosci. 2023;13(1):182.

[186] Zeng Z, Xu FY, Zheng H, et al. LncRNA-MTA2TR functions as a promoter in pancreatic cancer via driving deacetylation-dependent accumulation of HIF-1α. Theranostics. 2019;9(18):5298-5314.

[187] Niu Y, Jin Y, Deng SC, et al. MiRNA-646-mediated reciprocal repression between HIF-1α and MIIP contributes to tumorigenesis of pancreatic cancer. Oncogene. 2018;37(13):1743-1758.

[188] Zhang Y, Ren YJ, Guo LC, et al. Nucleus accumbens-associated protein-1 promotes glycolysis and survival of hypoxic tumor cells via the HDAC4-HIF-1α axis. Oncogene. 2017;36(29):4171-4181.

[189] Fischer C, Leithner K, Wohlkoenig C, et al. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization. Mol Cancer. 2015;14:4.

[190] Geng H, Harvey CT, Pittsenbarger J, et al. HDAC4 protein regulates HIF1α protein lysine acetylation and cancer cell response to hypoxia. J Biol Chem. 2011;286(44):38095-38102.

[191] Wu HT, Kuo YC, Hung JJ, et al. K63-polyubiquitinated HAUSP deubiquitinates HIF-1α and dictates H3K56 acetylation promoting hypoxia-induced tumour progression. Nat Commun. 2016;7:13644.

[192] Yeh IJ, Ogba N, Bensigner H, Welford SM, Montano MM. HEXIM1 down-regulates hypoxia-inducible factor-1α protein stability. Biochem J. 2013;456(2):195-204.

[193] Yoo YG, Kong G, Lee MO. Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1. Embo j. 2006;25(6):1231-1241.

[194] Yoo YG, Na TY, Seo HW, et al. Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells. Oncogene. 2008;27(24):3405-3413.

[195] Liu Y, Zhang JB, Qin Y, et al. PROX1 promotes hepatocellular carcinoma metastasis by way of up-regulating hypoxia-inducible factor 1α expression and protein stability. Hepatology. 2013;58(2):692-705.

[196] Chang CC, Lin MT, Lin BR, et al. Effect of connective tissue growth factor on hypoxia-inducible factor 1alpha degradation and tumor angiogenesis. J Natl Cancer Inst. 2006;98(14):984-995.

[197] Rojo de la Vega M, Chapman E, Zhang DD. NRF2 and the hallmarks of cancer. Cancer Cell. 2018;34(1):21-43.

[198] Hayes JD, Dinkova-Kostova AT, Tew KD. Oxidative stress in cancer. Cancer Cell. 2020;38(2):167-197.

[199] Menegon S, Columbano A, Giordano S. The dual roles of NRF2 in cancer. Trends Mol Med. 2016;22(7):578-593.

[200] Jun L, Chen W, Han L, Yanmin L, Qinglei Z, Pengfei Z. Protocadherin 20 promotes ferroptosis by suppressing the expression of Sirtuin 1 and promoting the acetylation of nuclear factor erythroid 2-related factor 2 in hepatocellular carcinoma. Int J Biochem Cell Biol. 2023;156:106363.

[201] Chen D, Tavana O, Chu B, et al. NRF2 is a major target of ARF in p53-independent tumor suppression. Mol Cell. 2017;68(1):224-232. e224.

[202] Chen Z, Ye X, Tang N, et al. The histone acetylranseferase hMOF acetylates Nrf2 and regulates anti-drug responses in human non-small cell lung cancer. Br J Pharmacol. 2014;171(13):3196-3211.

[203] Fang X, Lee YH, Jang JH, et al. ARD1 stabilizes NRF2 through direct interaction and promotes colon cancer progression. Life Sci. 2023;313:121217.

[204] Duffy MJ, O’Grady S, Tang M, Crown J. MYC as a target for cancer treatment. Cancer Treat Rev. 2021;94:102154.

[205] Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res. 2009;15(21):6479-6483.

[206] Liu R, Gou D, Xiang J, et al. O-GlcNAc modified-TIP60/KAT5 is required for PCK1 deficiency-induced HCC metastasis. Oncogene. 2021;40(50):6707-6719.

[207] Wei X, Cai S, Boohaker RJ, et al. KAT5 promotes invasion and metastasis through C-MYC stabilization in ATC. Endocr Relat Cancer. 2019;26(1):141-151.

[208] Ren X, Yu J, Guo L, Ma H. Circular RNA circRHOT1 contributes to pathogenesis of non-small cell lung cancer by epigenetically enhancing C-MYC expression through recruiting KAT5. Aging (Albany NY). 2021;13(16):20372-20382.

[209] Zhang M, Zhang L, Zhou M, et al. Anti silencing function 1B promotes the progression of pancreatic cancer by activating c Myc. Int J Oncol. 2023;62(1):8.

[210] Jiao D, Sun R, Ren X, et al. Lipid accumulation-mediated histone hypoacetylation drives persistent NK cell dysfunction in anti-tumor immunity. Cell Rep. 2023;42(10):113211.

[211] Maneix L, Iakova P, Moree SE, et al. Proteasome inhibitors silence oncogenes in multiple myeloma through localized histone deacetylase 3 (HDAC3) stabilization and chromatin condensation. Cancer Res Commun. 2022;2(12):1693-1710.

[212] Wu H, Yang TY, Li Y, et al. Tumor necrosis factor receptor-associated factor 6 promotes hepatocarcinogenesis by interacting with histone deacetylase 3 to enhance c-Myc gene expression and protein stability. Hepatology. 2020;71(1):148-163.

[213] Kang YK, Schiff R, Ko L, et al. Dual roles for coactivator activator and its counterbalancing isoform coactivator modulator in human kidney cell tumorigenesis. Cancer Res. 2008;68(19):7887-7896.

[214] Zhang M, Pan Y, Tang D, et al. Low levels of pyruvate induced by a positive feedback loop protects cholangiocarcinoma cells from apoptosis. Cell Commun Signal. 2019;17(1):23.

[215] Zhu Y, Hu H, Yuan Z, et al. LncRNA NEAT1 remodels chromatin to promote the 5-Fu resistance by maintaining colorectal cancer stemness. Cell Death Dis. 2020;11(11):962.

[216] Lu X, Xin DE, Du JK, et al. Loss of LOXL2 promotes uterine hypertrophy and tumor progression by enhancing H3K36ac-dependent gene expression. Cancer Res. 2022;82(23):4400-4413.

[217] Hwang IY, Roe JS, Seol JH, Kim HR, Cho EJ, Youn HD. pVHL-mediated transcriptional repression of c-Myc by recruitment of histone deacetylases. Mol Cells. 2012;33(2):195-201.

[218] Qiao L, Zhang Q, Zhang W, Chen JJ. The lysine acetyltransferase GCN5 contributes to human papillomavirus oncoprotein E7-induced cell proliferation via up-regulating E2F1. J Cell Mol Med. 2018;22(11):5333-5345.

[219] Mao B, Zhao G, Lv X, et al. Sirt1 deacetylates c-Myc and promotes c-Myc/Max association. Int J Biochem Cell Biol. 2011;43(11):1573-1581.

[220] Panwalkar P, Tamrazi B, Dang D, et al. Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas. Sci Transl Med. 2021;13(614):eabc0497.

[221] Gandhirajan A, Roychowdhury S, Kibler C, et al. SIRT2-PFKP interaction dysregulates phagocytosis in macrophages with acute ethanol-exposure. Front Immunol. 2022;13:1079962.

[222] Lee JH, Liu R, Li J, et al. EGFR-phosphorylated platelet isoform of phosphofructokinase 1 promotes PI3K activation. Mol Cell. 2018;70(2):197-210. e197.

[223] Prentki M, Madiraju SR. Glycerolipid metabolism and signaling in health and disease. Endocr Rev. 2008;29(6):647-676.

[224] Zhang QW, Lin XL, Dai ZH, et al. Hypoxia and low-glucose environments co-induced HGDILnc1 promote glycolysis and angiogenesis. Cell Death Discov. 2024;10(1):132.

[225] Cha Y, Han MJ, Cha HJ, et al. Metabolic control of primed human pluripotent stem cell fate and function by the miR-200c-SIRT2 axis. Nat Cell Biol. 2017;19(5):445-456.

[226] Inoue E, Yamauchi J. AMP-activated protein kinase regulates PEPCK gene expression by direct phosphorylation of a novel zinc finger transcription factor. Biochem Biophys Res Commun. 2006;351(4):793-799.

[227] Meng W, Lu X, Wang G, Xiao Q, Gao J. ZNF692 drives malignant development of hepatocellular carcinoma cells by promoting ALDOA-dependent glycolysis. Funct Integr Genomics. 2024;24(2):53.

[228] Jiao JW, Zhan XH, Wang JJ, et al. LOXL2-dependent deacetylation of aldolase A induces metabolic reprogramming and tumor progression. Redox Biol. 2022;57:102496.

[229] Fang M, Jin A, Zhao Y, Liu X. Homocysteine induces glyceraldehyde-3-phosphate dehydrogenase acetylation and apoptosis in the neuroblastoma cell line Neuro2a. Braz J Med Biol Res. 2016;49(2):e4543.

[230] Hara MR, Agrawal N, Kim SF, et al. S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding. Nat Cell Biol. 2005;7(7):665-674.

[231] Ventura M, Mateo F, Serratosa J, et al. Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase is regulated by acetylation. Int J Biochem Cell Biol. 2010;42(10):1672-1680.

[232] Li T, Liu M, Feng X, et al. Glyceraldehyde-3-phosphate dehydrogenase is activated by lysine 254 acetylation in response to glucose signal. J Biol Chem. 2014;289(6):3775-3785.

[233] Qian X, Li X, Lu Z. Protein kinase activity of the glycolytic enzyme PGK1 regulates autophagy to promote tumorigenesis. Autophagy. 2017;13(7):1246-1247.

[234] Qian X, Li X, Cai Q, et al. Phosphoglycerate kinase 1 phosphorylates beclin1 to induce autophagy. Mol Cell. 2017;65(5):917-931. e916.

[235] Hu H, Zhu W, Qin J, et al. Acetylation of PGK1 promotes liver cancer cell proliferation and tumorigenesis. Hepatology. 2017;65(2):515-528.

[236] Wang S, Jiang B, Zhang T, et al. Insulin and mTOR pathway regulate HDAC3-mediated deacetylation and activation of PGK1. PLoS Biol. 2015;13(9):e1002243.

[237] Fu G, Li ST, Jiang Z, et al. PGAM5 deacetylation mediated by SIRT2 facilitates lipid metabolism and liver cancer proliferation. Acta Biochim Biophys Sin (Shanghai). 2023;55(9):1370-1379.

[238] Xu Y, Li F, Lv L, et al. Oxidative stress activates SIRT2 to deacetylate and stimulate phosphoglycerate mutase. Cancer Res. 2014;74(13):3630-3642.

[239] Hallows WC, Yu W, Denu JM. Regulation of glycolytic enzyme phosphoglycerate mutase-1 by Sirt1 protein-mediated deacetylation. J Biol Chem. 2012;287(6):3850-3858.

[240] Zheng Y, Wu C, Yang J, et al. Insulin-like growth factor 1-induced enolase 2 deacetylation by HDAC3 promotes metastasis of pancreatic cancer. Signal Transduct Target Ther. 2020;5(1):53.

[241] Kim AY, Lim B, Choi J, Kim J. The TFG-TEC oncoprotein induces transcriptional activation of the human β-enolase gene via chromatin modification of the promoter region. Mol Carcinog. 2016;55(10):1411-1423.

[242] Zhang R, Shen M, Wu C, et al. HDAC8-dependent deacetylation of PKM2 directs nuclear localization and glycolysis to promote proliferation in hepatocellular carcinoma. Cell Death Dis. 2020;11(12):1036.

[243] Lei H, Yang L, Wang Y, et al. JOSD2 regulates PKM2 nuclear translocation and reduces acute myeloid leukemia progression. Exp Hematol Oncol. 2022;11(1):42.

[244] Gao F, Zhang X, Wang S, et al. TSP50 promotes the Warburg effect and hepatocyte proliferation via regulating PKM2 acetylation. Cell Death Dis. 2021;12(6):517.

[245] Lv L, Li D, Zhao D, et al. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol Cell. 2011;42(6):719-730.

[246] Park SH, Ozden O, Liu G, et al. SIRT2-mediated deacetylation and tetramerization of pyruvate kinase directs glycolysis and tumor growth. Cancer Res. 2016;76(13):3802-3812.

[247] Bhardwaj A, Das S. SIRT6 deacetylates PKM2 to suppress its nuclear localization and oncogenic functions. Proc Natl Acad Sci USA. 2016;113(5):E538-547.

[248] Forkasiewicz A, Dorociak M, Stach K, Szelachowski P, Tabola R, Augoff K. The usefulness of lactate dehydrogenase measurements in current oncological practice. Cell Mol Biol Lett. 2020;25:35.

[249] Shi L, Yan H, An S, et al. SIRT5-mediated deacetylation of LDHB promotes autophagy and tumorigenesis in colorectal cancer. Mol Oncol. 2019;13(2):358-375.

[250] Cui Y, Qin L, Wu J, et al. SIRT3 enhances glycolysis and proliferation in SIRT3-expressing gastric cancer cells. PLoS One. 2015;10(6):e0129834.

[251] Zhao D, Zou SW, Liu Y, et al. Lysine-5 acetylation negatively regulates lactate dehydrogenase A and is decreased in pancreatic cancer. Cancer Cell. 2013;23(4):464-476.

[252] Goudarzi A. The recent insights into the function of ACAT1: a possible anti-cancer therapeutic target. Life Sci. 2019;232:116592.

[253] Fan J, Shan C, Kang HB, et al. Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex. Mol Cell. 2014;53(4):534-548.

[254] Ristic B, Bhutia YD, Ganapathy V. Cell-surface G-protein-coupled receptors for tumor-associated metabolites: a direct link to mitochondrial dysfunction in cancer. Biochim Biophys Acta Rev Cancer. 2017;1868(1):246-257.

[255] Ozden O, Park SH, Wagner BA, et al. SIRT3 deacetylates and increases pyruvate dehydrogenase activity in cancer cells. Free Radic Biol Med. 2014;76:163-172.

[256] Sawant Dessai A, Dominguez MP, Chen UI, et al. Transcriptional repression of SIRT3 potentiates mitochondrial aconitase activation to drive aggressive prostate cancer to the bone. Cancer Res. 2021;81(1):50-63.

[257] Zhuo FF, Li L, Liu TT, et al. Lycorine promotes IDH1 acetylation to induce mitochondrial dynamics imbalance in colorectal cancer cells. Cancer Lett. 2023;573:216364.

[258] Yang H, Zhao X, Liu J, et al. TNFα-induced IDH1 hyperacetylation reprograms redox homeostasis and promotes the chemotherapeutic sensitivity. Oncogene. 2023;42(1):35-48.

[259] Wang B, Ye Y, Yang X, et al. SIRT2-dependent IDH1 deacetylation inhibits colorectal cancer and liver metastases. EMBO Rep. 2020;21(4):e48183.

[260] Zou X, Zhu Y, Park SH, et al. SIRT3-mediated dimerization of IDH2 directs cancer cell metabolism and tumor growth. Cancer Res. 2017;77(15):3990-3999.

[261] Yu W, Denu RA, Krautkramer KA, et al. Loss of SIRT3 provides growth advantage for B cell malignancies. J Biol Chem. 2016;291(7):3268-3279.

[262] Yu W, Dittenhafer-Reed KE, Denu JM. SIRT3 protein deacetylates isocitrate dehydrogenase 2 (IDH2) and regulates mitochondrial redox status. J Biol Chem. 2012;287(17):14078-14086.

[263] Li ST, Huang D, Shen S, et al. Myc-mediated SDHA acetylation triggers epigenetic regulation of gene expression and tumorigenesis. Nat Metab. 2020;2(3):256-269.

[264] Bai Q, Jin W, Chen F, et al. KLF8 promotes the survival of lung adenocarcinoma during nutrient deprivation by regulating the pentose phosphate pathway through SIRT2. Front Biosci (Landmark Ed). 2024;29(1):27.

[265] Zhang X, Gao F, Ai H, et al. TSP50 promotes hepatocyte proliferation and tumour formation by activating glucose-6-phosphate dehydrogenase (G6PD). Cell Prolif. 2021;54(4):e13015.

[266] Ni Y, Yang Z, Agbana YL, et al. Silent information regulator 2 promotes clear cell renal cell carcinoma progression through deacetylation and small ubiquitin-related modifier 1 modification of glucose 6-phosphate dehydrogenase. Cancer Sci. 2021;112(10):4075-4086.

[267] Wang YP, Zhou LS, Zhao YZ, et al. Regulation of G6PD acetylation by SIRT2 and KAT9 modulates NADPH homeostasis and cell survival during oxidative stress. Embo j. 2014;33(12):1304-1320.

[268] Xu SN, Wang TS, Li X, Wang YP. SIRT2 activates G6PD to enhance NADPH production and promote leukaemia cell proliferation. Sci Rep. 2016;6:32734.

[269] Shan C, Lu Z, Li Z, et al. 4-hydroxyphenylpyruvate dioxygenase promotes lung cancer growth via pentose phosphate pathway (PPP) flux mediated by LKB1-AMPK/HDAC10/G6PD axis. Cell Death Dis. 2019;10(7):525.

[270] Shan C, Elf S, Ji Q, et al. Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growth. Mol Cell. 2014;55(4):552-565.

[271] Wang P, Li R, Li Y, et al. Berberine alleviates non-alcoholic hepatic steatosis partially by promoting SIRT1 deacetylation of CPT1A in mice. Gastroenterol Rep (Oxf). 2023;11:goad032.

[272] Helsley RN, Park SH, Vekaria HJ, et al. Ketohexokinase-C regulates global protein acetylation to decrease carnitine palmitoyltransferase 1a-mediated fatty acid oxidation. J Hepatol. 2023;79(1):25-42.

[273] Fan X, Wang Y, Cai X, et al. CPT2 K79 acetylation regulates platelet life span. Blood Adv. 2022;6(17):4924-4935.

[274] Zhang YK, Qu YY, Lin Y, et al. Enoyl-CoA hydratase-1 regulates mTOR signaling and apoptosis by sensing nutrients. Nat Commun. 2017;8(1):464.

[275] Zhang X, Xu Y, Li S, et al. SIRT2-mediated deacetylation of ACLY promotes the progression of oesophageal squamous cell carcinoma. J Cell Mol Med. 2024;28(6):e18129.

[276] Zhang S, Zhang Z, Liu X, et al. LncRNA-encoded micropeptide ACLY-BP drives lipid deposition and cell proliferation in clear cell renal cell carcinoma via maintenance of ACLY acetylation. Mol Cancer Res. 2023;21(10):1064-1078.

[277] Tian Y, Ma J, Wang H, et al. BCAT2 promotes melanoma progression by activating lipogenesis via the epigenetic regulation of FASN and ACLY expressions. Cell Mol Life Sci. 2023;80(11):315.

[278] Zhou F, Ai W, Zhang Y, et al. ARHGEF3 regulates the stability of ACLY to promote the proliferation of lung cancer. Cell Death Dis. 2022;13(10):870.

[279] Lin R, Tao R, Gao X, et al. Acetylation stabilizes ATP-citrate lyase to promote lipid biosynthesis and tumor growth. Mol Cell. 2013;51(4):506-518.

[280] Xu LX, Hao LJ, Ma JQ, Liu JK, Hasim A. SIRT3 promotes the invasion and metastasis of cervical cancer cells by regulating fatty acid synthase. Mol Cell Biochem. 2020;464(1-2):11-20.

[281] Lin HP, Cheng ZL, He RY, et al. Destabilization of fatty acid synthase by acetylation inhibits de novo lipogenesis and tumor cell growth. Cancer Res. 2016;76(23):6924-6936.

[282] Gang X, Yang Y, Zhong J, et al. P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth. Oncotarget. 2016;7(12):15135-15149.

[283] Gao X, Lin SH, Ren F, et al. Acetate functions as an epigenetic metabolite to promote lipid synthesis under hypoxia. Nat Commun. 2016;7:11960.

[284] Camarero N, Nadal A, Barrero MJ, Haro D, Marrero PF. Histone deacetylase inhibitors stimulate mitochondrial HMG-CoA synthase gene expression via a promoter proximal Sp1 site. Nucleic Acids Res. 2003;31(6):1693-1703.

[285] Ando H, Horibata Y, Aoyama C, et al. Side-chain oxysterols suppress the transcription of CTP: phosphoethanolamine cytidylyltransferase and 3-hydroxy-3-methylglutaryl-CoA reductase by inhibiting the interaction of p300 and NF-Y, and H3K27 acetylation. J Steroid Biochem Mol Biol. 2019;195:105482.

[286] Xu D, Luo HW, Hu W, et al. Intrauterine programming mechanism for hypercholesterolemia in prenatal caffeine-exposed female adult rat offspring. Faseb j. 2018;32(10):5563-5576.

[287] Zhang T, Cui Y, Wu Y, et al. Mitochondrial GCN5L1 regulates glutaminase acetylation and hepatocellular carcinoma. Clin Transl Med. 2022;12(5):e852.

[288] Wang T, Lu Z, Han T, Wang Y, Gan M, Wang JB. Deacetylation of glutaminase by HDAC4 contributes to lung cancer tumorigenesis. Int J Biol Sci. 2022;18(11):4452-4465.

[289] Hu K, Ding Y, Zhu H, et al. Glutamate dehydrogenase1 supports HIF-1α stability to promote colorectal tumorigenesis under hypoxia. Embo j. 2023;42(12):e112675.

[290] Li M, Chiang YL, Lyssiotis CA, et al. Non-oncogene addiction to SIRT3 plays a critical role in lymphomagenesis. Cancer Cell. 2019;35(6):916-931. e919.

[291] Hu T, Shukla SK, Vernucci E, et al. Metabolic rewiring by loss of Sirt5 promotes kras-induced pancreatic cancer progression. Gastroenterology. 2021;161(5):1584-1600.

[292] Wang C, Wan X, Yu T, et al. Acetylation stabilizes phosphoglycerate dehydrogenase by disrupting the interaction of E3 ligase RNF5 to promote breast tumorigenesis. Cell Rep. 2020;32(6):108021.

[293] Cai LY, Chen SJ, Xiao SH, et al. Targeting p300/CBP attenuates hepatocellular carcinoma progression through epigenetic regulation of metabolism. Cancer Res. 2021;81(4):860-872.

[294] Wei Z, Song J, Wang G, et al. Deacetylation of serine hydroxymethyl-transferase 2 by SIRT3 promotes colorectal carcinogenesis. Nat Commun. 2018;9(1):4468.

[295] Pu J, Liu T, Wang X, et al. Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives. Exp Hematol Oncol. 2024;13(1):45.

[296] Zhu M, Han Y, Gu T, et al. Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway. Cell Rep. 2024;43(4):114065.

[297] Guertin DA, Wellen KE. Acetyl-CoA metabolism in cancer. Nat Rev Cancer. 2023;23(3):156-172.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.